Anupam Rasayan India Limited has informed the Exchange regarding a press release dated August 13, 2025, titled "Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2025".
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Anupam Rasayan India reported strong Q1FY26 results with consolidated total revenue of ₹4,907 million, up 89% year-on-year from ₹2,603 million in Q1FY25. EBITDA (including other income) rose 118% YoY to ₹1,292 million, translating to a 26% EBITDA margin. Profit After Tax jumped 297% YoY to ₹485 million from ₹122 million. The company highlighted that pharma and polymer businesses are performing well, with a recovery in the agrochemical segment, while exports accounted for 58% of revenue. Management noted that the order book now stands at ₹14,646 crore following two new agreements with Japanese and US-based multinationals.
Sharp double-digit growth across revenue, EBITDA, and profit signals a strong demand recovery and improving operating leverage, likely to be viewed positively by shareholders. The expanding order book and new multinational contracts provide good revenue visibility going forward.